214 related articles for article (PubMed ID: 15548440)
21. New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
Saad F
Cancer Treat Rev; 2008 Apr; 34(2):183-92. PubMed ID: 18061356
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer and bone metastases: medical treatment.
Clark PE; Torti FM
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S148-57. PubMed ID: 14600605
[TBL] [Abstract][Full Text] [Related]
23. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates for treatment and prevention of bone metastases.
Michaelson MD; Smith MR
J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
[TBL] [Abstract][Full Text] [Related]
25. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
26. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
27. Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases.
Serefoglu EC; Balbay MD
Med Hypotheses; 2009 Sep; 73(3):387-8. PubMed ID: 19403241
[TBL] [Abstract][Full Text] [Related]
28. The systemic treatment of bone metastases.
Houston SJ; Rubens RD
Clin Orthop Relat Res; 1995 Mar; (312):95-104. PubMed ID: 7543393
[TBL] [Abstract][Full Text] [Related]
29. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
30. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease.
Saad F; Lipton A
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S17-23. PubMed ID: 18068486
[TBL] [Abstract][Full Text] [Related]
31. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
32. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
[TBL] [Abstract][Full Text] [Related]
33. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
Rodrigues P; Hering F; Campagnari JC
Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
[TBL] [Abstract][Full Text] [Related]
34. Role of bisphosphonates in prostate cancer.
Saad F; Schulman CC
Eur Urol; 2004 Jan; 45(1):26-34. PubMed ID: 14667511
[TBL] [Abstract][Full Text] [Related]
35. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
[TBL] [Abstract][Full Text] [Related]
36. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
[TBL] [Abstract][Full Text] [Related]
37. Incidence and risk factors for low trauma fractures in men with prostate cancer.
Ahlborg HG; Nguyen ND; Center JR; Eisman JA; Nguyen TV
Bone; 2008 Sep; 43(3):556-60. PubMed ID: 18585119
[TBL] [Abstract][Full Text] [Related]
38. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
[TBL] [Abstract][Full Text] [Related]
39. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
[TBL] [Abstract][Full Text] [Related]
40. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
McLeod N; Huynh CC; Rashid P
Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]